Preliminary unaudited U.S. NeuroStar Advanced Therapy System revenue is expected to be approximately $4.5 million. In the quarter, the Company shipped 59 systems. Preliminary unaudited U.S. Treatment Session revenue is expected to be over $14.5 million a Company record, and an increase of approximately 20% over the fourth quarter of 2022. Local consumable revenue increased by over 33% over the fourth quarter 2022. The Company generated positive cash flow of over $1 million in the fourth quarter 2023, ending 2023 with cash and cash equivalents at approximately $59 million.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on STIM:
- Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results
- Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
- Neuronetics receives 510(k) clearance for NeuroSite Coil Placement Accessory
- NeuroStar TMS Receives Expanded Regulatory Approval in Japan
- Neuronetics’s NeuroStar TMS receives expanded regulatory approval in Japan
